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ABSTRACT
The in vitro efficacy of the disintegrin echistatin was tested on a high-metastatic 
variant of 143B human osteosarcoma, 143B-LM4, which over-expresses αvβ3 integrin. 
Echistatin is an RGD cyclic peptide and an antagonist of αvβ3 integrin. In the present 
study, echistatin inhibited cell proliferation, migration, invasion, and adhesion of 
143B-LM4 cells. 143B-LM4 cell proliferation decreased after treatment with echistatin 
in a time-dependent and dose-dependent manner (P<0.01). In vitro migration and 
invasion of 143B-LM4 cells were also inhibited by echistatin in a dose-dependent 
manner (P<0.01, respectively). Cell adhesion to vitronectin of 143B-LM4 cells was 
also inhibited by echistatin in a dose-dependent manner (P<0.01). These results 
suggest that αvβ3 integrin may be an effective target for osteosarcoma.
INTRODUCTION
Osteosarcoma is the most common bone cancer in 
children and adolescents [1-3]. Osteosarcoma usually arises 
in the distal femur and proximal tibia and proximal humerus.
Development of neo-adjuvant chemotherapy has 
increased the rate of overall survival and has enabled 
surgery, but the failure rate is still high, causing death in 
children and adolescents [4-7].
Novel more effective targets for osteosarcoma 
therapy are therefore needed. Toward this goal, αvβ3 
integrin-over-expressing high-metastatic variants of the 
human osteosarcoma cell line 143B were previously 
isolated and termed 143B-LM4.
Over-expression of αvβ3 integrin in the variant 
selected for high-metastasis suggested that integrin maybe 
a promising target for osteosarcoma. The 143B-LM4 cells 
expressed green fluorescent protein (GFP) in the nucleus 
and red fluorescent protein (RFP) in the cytoplasm, and 
therefore could be imaged down to the subcellular level in 
vitro and in vivo [8].
Lung seeding by 143B-LM4 cells was directly 
imaged and found to be greatly inhibited by the anti-β1 
integrin monoclonal antibody, AIIB2. AIIB2 also 
significantly inhibited spontaneous lung metastasis and 
increased survival of mice with orthotopically-growing 
143B-RFP [9].
In the present study, we tested echistatin, a cyclic 
RGD peptide antagonist of αvβ3 integrin (disintegrin) 
[10], as a molecular-targeting drug in human metastatic 
osteosarcoma in vitro on the highly metastatic 143B-LM4 
cell line which over-expresses αvβ3 integrin described 
above.
RESULTS AND DISCUSSION
Dual-color-labeled GFP- and RFP-expressing 
143B-LM4 cells
The high-metastatic integrin-over-expressing 143B-
LM4 cells have a strikingly bright GFP in the nucleus and 
RFP in the cytoplasm, in vitro (Figure 1).
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Echistatin inhibits cell proliferation, migration, 
invasion, and adhesion of 143B-LM4 cells
To determine whether echistatin inhibited 143B-
LM4 cell proliferation, 143B-LM4 cells were treated 
with echistatin at various concentrations. 143B-LM4 cell 
proliferation decreased after treatment with echistatin 
in a time-dependent and a dose-dependent manner 
(P<0.01) (Figure 2A). After 24 hr treatment, 143B-LM4 
cell proliferation was decreased to 44.0% at 0.5 μg/mL; 
34.8% at 1.0 μg/mL echistatin; and 28.1% at 5.0 μg/mL 
echistatin, compared to control (P<0.01, respectively). At 
72 hr after treatment, cell proliferation decreased to 74.2% 
at 0.1 μg/mL; 35.1% at 0.5 μg/mL echistatin, 19.1% at 1.0 
μg/mL; and to 4.2% at 5.0 μg/mL echistatin, compared to 
control (P<0.01, respectively). Fluorescence microscopy 
showed that cell number decreased in a dose-dependent 
manner and the cancer cells appeared more shrunken at a 
high concentration of echistatin (Figure 2B).
The effect of echistatin on the ability of 143B-LM4 
cells to migrate was then tested. In vitro, migration of 
143B-LM4 cells decreased to 59.4% at 1.0 μg/mL and to 
8.5% at 5.0 μg/mL echistatin, compared to control (P<0.01 
respectively) (Figure 3A).
Invasion of 143B-LM4 cells decreased to 23.3% at 
0.5 μg/mL, 15.7% at 1.0 μg/mL and to 9.0% at 5.0 μg/
mL echistatin, compared to control (P<0.01, respectively) 
(Figure 3B).
To determine whether echistatin could inhibit 
adhesion to vitronectin, which is a specific ligand of αvβ3 
integrin, 143B-LM4 cells were seeded on vitronectin coated-
dishes and treated with echistatin. Adhesion to vitronectin of 
143B-LM4 cells decreased to 18.5% at 0.5 μg/mL, 14.6% at 
1.0 μg/mL and to 6.5% at 5.0 μg/mL echistatin, compared to 
control (P<0.01, respectively) (Figure 4).
Aggressive chemotherapy of osteosarcoma in 
patients with metastatic or recurrent disease, most 
commonly in the lung [11-13], still results in poor 
prognosis with less than a 20% 5-year overall survival rate 
[14-16]. Therefore, novel targets are needed to overcome 
recurrence or metastasis and to improve the disease-free 
survival rate.
In the present study, we demonstrated that echistatin 
resulted in a significant decrease of cell proliferation, 
Figure 1: Dual-color selected 143B-LM4 human osteosarcoma cells expressing GFP in the nucleus and RFP in the 
cytoplasm in vitro. Images were obtained with a Fluoview FV1000 laser-scanning confocal microscope (Olympus Corp., Tokyo, Japan). 
GFP was excited at 488 nm, RFP at 543nm. Magnification 60x. Scale bar: 50 µm.
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migration, invasion, and adhesion of 143B-LM4 cells 
in vitro. As 143B-LM4 is a high-metastatic variant that 
over-expresses αvβ3 integrin, these results suggest that αvβ3 
integrin may be an effective target for osteosarcoma that 
has future clinical potential.
Previously-developed concepts and strategies of 
highly-selective tumor targeting can take advantage of 
molecular targeting of tumors, including tissue-selective 
therapy which focuses on unique differences between 
normal and tumor tissues [17-22].
Figure 2: Echistatin decreased proliferation of 143B-LM4 cells in vitro. A. Efficacy of echistatin on 143B-LM4 cell proliferation. 
Proliferation of 143B-LM4 cells was inhibited by echistatin and decreased in a time-dependent and a dose-dependent manner (P<0.01). Error 
bars: SEM. B. visualization of the efficacy of echistatin at various concentrations on 143B-LM4 cell proliferation at 72 hours. Cell number 
decreased in a dose-dependent manner. Images were obtained with the Olympus IX71 fluorescence microscope. Magnification, 20×.
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Figure 3: Echistatin decreased migration and invasion of 143B-LM4 cells in vitro. A. Efficacy of echistatin on 143B-LM4 cell 
migration in vitro. 143B-LM4 cells were seeded into the upper compartment of transwell chambers (Corning® HTS Transwell-96 uncoated 
plates, (Tewksbury, MA). Migration of 143B-LM4 cells decreased in a dose-dependent manner (P<0.01). Error bars: SEM. B. Efficacy of 
echistatin on 143B-LM4 invasion in vitro. 143B-LM4 cells were seeded into the upper compartment of transwell chambers with the surface 
coated with a basement membrane extract. Invasion of 143B-LM4 cells decreased in a dose-dependent manner (P<0.01). Error bars: SEM. 
Absorbance was evaluated with a plate reader after cells which migrated or invaded were treated with MTS.
Figure 4: Echistatin decreased adhesion to vitronectin of 143B-LM4 cells in vitro. Efficacy of echistatin on 143B-LM4 
cell adhesion to Vitronectin (Trevigen, Gaithersburg, MD) in vitro (Corning® HTS Transwell-96 plates (Tewksbury, MA) coated with 
Vitronectin. Adhesion of 143B-LM4 cells decreased in a dose-dependent manner (P<0.01). Error bars: SEM. Absorbance was evaluated 
with a plate reader after adherent cells were treated with MTS.
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MATERIALS AND METHODS
Cells
143B-LM4 cells [8] expressing GFP in the nucleus 
and RFP in the cytoplasm (Figure 1) were generated, 
as previously described, and maintained in RPMI 1640 
medium (Irvine Scientific, Santa Ana, CA) containing 
15% fetal bovine serum (FBS) (Omega Scientific, San 
Diego, CA) and 1% penicillin/streptomycin at 37°C in 
5% CO2.
Drug
Echistatin [10] (Tocris Bioscience, Ellisville, MO) 
was diluted with distilled water and stored at -20°C.
Cell proliferation assay
143B-LM4 cells (5×103) were added to 96-well 
tissue culture plates and placed overnight at 37°C in 
a CO2 incubator. The cells were treated with various 
concentrations of echistatin. At various time intervals, 100 
µl of fresh medium was replenished and 20 µl of 3-(4, 
5-dimethylatiazol-2yl)-5-(3-carboxymethoxyphenyl)-2H-
tetrazolium (MTS) (Promega, Madison, WI) was added to 
the cells. After incubation for 1 h, absorbance was measured 
using a microplate reader (TECAN Group Ltd., Männedorf, 
Switzerland) at 490 nm. The assay was performed in 
triplicate and at least twice. Cell images were observed with 
a fluorescence microscope (IX71, Olympus Corp., Tokyo, 
Japan).
Migration and invasion assay
An in vitro migratory/invasiveness assay was carried 
out with Corning® (Tewksbury, MA) HTS Transwell-96 
plates uncoated or coated, respectively, with a basement 
membrane extract (Trevigen, Gaithersburg, MD) 
according to manufacturer’s instructions. 143B-LM4 
cells (5×104) were added to the upper chamber and various 
concentrations of echistatin were added to the lower 
chamber (0.5 µg/mL, 1.0 µg/mL, 5.0 µg/m), for both 
the migration and invasion assays. The lower chamber 
had the same conditions for the migration and invasion 
assays. For the migration assay, an uncoated well was 
used for the upper chamber. For the invasion assay, a well 
coated with a basement membrane was used as the upper 
chamber. For both assays, cancer cells were seeded in the 
upper chamber. The plate was placed for 24 h at 37°C in 
a tissue culture incubator. After incubation for 24 h, 100 
µl of fresh medium was gently replenished in the lower 
chamber and 20 µl MTS was added to the lower chamber 
to determine cell viability. After incubation for 1 h, the 
absorbance was measured using a microplate reader at 490 
nm. The assays were performed in triplicate and at least 
twice, independently.
Adhesion assay
The adhesion assay was carried out with 
CultureCoat® Vitronectin 96-well dishes (Trevigen) 
according to the manufacturer’s instructions. 143B-LM4 
cells were labeled with 2 µM calcein AM (Invitrogen, 
Carlsbad, CA), harvested and then re-suspended in 
medium to a final concentration of 1.5×105 cells/ml. 
Only live cells can absorb this agent. 143B-LM4 cells 
(1.5×104/100 µl) were added to each well and were 
either left untreated or treated with echistatin (0.5 µg/
mL, 1.0 µg/mL, 5.0 µg/mL), and placed for 1 h at 37°C 
in a CO2 incubator. The medium was gently removed. 
The wells were washed twice gently with PBS. The 
fluorescence intensity of the cells remaining on the 
bottom of the well was measured using a SPECTRAmax 
GEMINI Dual-Scanning Microplate Spectrofluorometer, 
(Molecular Devices, Sunnyvale, CA) at an excitation/
emission wavelength of 485/520 nm. The assay was 
performed in triplicate and at least twice independently.
Microscopy
In vitro 143B-LM4 cells were imaged with a 
Fluoview FV1000 laser-scanning confocal microscope 
(Olympus Corp., Tokyo, Japan) with a XLUMPLFL 60xW 
(0.90 NA) water-immersion objective [23]. GFP was 
excited at 488 nm, RFP at 543 nm. In the proliferation 
assay, cells were imaged with a fluorescence microscope 
(IX71, Olympus Corp., Tokyo, Japan).
Statistical analysis
The data are presented as mean ± SD or mean ± 
SEM. Statistical analysis was with ANOVA for multiple 
data sets. P-values of less than 0.05 were considered 
significant.
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